Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Protein Tyrosine Kinase-6 (PTK6)

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_305

Synonyms

Historical Background

The intracellular protein tyrosine kinase, PTK6 (also known as the breast tumor kinase, Brk), has been implicated in the development and progression of a number of different tumor types. First identified in three separate studies in the early 1990s, it was initially found in a study to determine which tyrosine kinases were expressed in human melanocytes and then the full-length sequence was subsequently cloned from metastatic breast cancer using a screen to identify novel kinases that were expressed in tumors, but not normal breast tissue. Identification of the murine ortholog, sik, in mouse intestinal cells was achieved by the generation of a library of kinase catalytic domains.

PTK6 is related to the Src family of protein kinases and belongs to a distinct class of enzymes which includes Frk and SRMS (reviewed Harvey and Burmi 2011) and expression produces two different isoforms as a result of alternative splicing (reviewed in Hussain and Harvey 2014) (Fig. 1).
Protein Tyrosine Kinase-6 (PTK6), Fig. 1

PTK6 domain structure. Schematic representation of the PTK6 gene structure and its products. All eight exons are contained in the PTK6 transcript, resulting in the production of a full length, fully functional protein. ALT-PTK6 arises as a result of alternative splicing, excluding exon 2. The subsequent protein shares the amino-terminus and the SH3 domain with its full-length isoform and a frameshift results in the carboxy-terminus being truncated and proline rich (PR)

Under normal physiological conditions, PTK6 expression is highly controlled and is usually limited to differentiating cells of epithelial origin. Several studies have reported that, pathologically (i.e., in disease tissue), PTK6 expression is increased in a number of different cancers compared to normal cells of the same tissue type (reviewed in Harvey and Burmi 2011).

The apparent disparity in PTK6 expression and the difference in proliferation status between cellular differentiation in normal tissues, where cells tend not be dividing; and the fact that tumors are highly proliferative (and cells are dividing rapidly) makes PTK6 an intriguing molecule for study, as there are likely to be both context- and function-specific differences that could be exploited in the development of antitumor therapies conferring benefit to patients.

Cellular Localization

PTK6 has been reported to have different functions in different tissue types; for example, in normal tissues PTK6’s role appears to be related to regulating the differentiation process, whereas in tumors PTK6 promotes proliferation and cell survival. Variations in cellular localization are thought to be associated with PTK6’s opposing roles in both differentiation and proliferation. Altered cellular localization will no doubt affect the variety of substrates and binding partners that are available for PTK6, thereby contributing to the different functions/effects that have been ascribed to PTK6 expression.

Myristoylation is a post- or cotranslational protein modification, whereby a fatty acid-derived group is attached to an N-terminal amino acid. Such modifications allow proteins to associate with membrane structures. Although PTK6 is structurally related to Src, it lacks the amino-terminal myristoylation site (Mitchell et al. 1994). Without a myristoylation site, PTK6 is not able to associate directly with the plasma membrane, and therefore cellular localization is not tightly regulated. Originally PTK6 was thought to be solely a cytoplasmic kinase; however, it is now known to be in different cellular compartments, including at the membrane via association with its binding partners as well as in the nucleus. Association of a protein to the plasma membrane can be mimicked by experimental inclusion of a myristoylation site. Adding a myristoylation site to the N-terminus, enhanced PTK6’s oncogenic role by promoting cell proliferation, survival, and migration of human embryonic kidney cells. Trapping PTK6 in the nucleus with a synthetic nuclear localization signal abrogated these effects (Kim and Lee 2009); these in vitro experimental effects are supported by evidence from human tumors demonstrating that normal prostate epithelial cells and well-differentiated prostate carcinomas had nuclear PTK6, whereas as poorly differentiated prostate cancers were found to have cytoplasmic PTK6 (reviewed in Goel and Lukong 2015). Increased expression of ALT-PTK6 resulted in an increase of constitutively active PTK6 in the nuclei of prostate tumor cells, suppressing proliferation (Brauer et al. 2011). Collectively, these studies suggest that PTK6’s oncogenic role may be dependent on its cellular localization; however, as PTK6 contains neither myristoylation sites nor nuclear localization signals, it is unclear how PTK6 delocalizes from one subcellular compartment to another and precisely which cellular signals are controlling this transition.

PTK6 Substrates and Binding Partners

As a tyrosine kinase with amino acid sequence homology to Src, PTK6 also has a similar domain structure consisting of SH2 and SH3 domains (which typically interact with phosphorylated tyrosines and proline-rich sequences, respectively) as well as a kinase domain (which phosphorylates its target substrates on tyrosine). It is therefore capable of phosphorylating a number of target molecules and there is a rapidly expanding list of known interacting proteins (summarized in Table 1). To date, over 35 PTK6-associated interactions have been identified (reviewed in Goel and Lukong 2015), but whether all of these interactions result in phosphorylation has not yet been determined. PTK6 is proposed to have some kinase-independent function (reviewed Harvey and Burmi 2011), suggesting that a functional kinase domain is not required for all of PTK6’s activities. It has been suggested that it may function as an adaptor molecule, and therefore it is highly likely that not all the interacting proteins will be substrates of PTK6’s kinase activity. It is possible that one of PTK6’s functions is to stabilize signaling complexes to allow phosphorylation of some of its interacting proteins and/or additional molecules within the complex by other kinases. This association in a large signaling complex, as an adaptor or scaffolding molecule, may also contribute to PTK6’s cellular localization.
Protein Tyrosine Kinase-6 (PTK6), Table 1

Summary of the localization of the major identified PTK6-interacting proteins (see Goel and Lukong (2015) for a comprehensive review of the biological outputs of these interactions). A further two substrates have been reported; however the proteins involved (which are 23 kDa and 100 kDa in size) have yet to be identified

Localization of PTK6-interacting proteins

Membrane proteins

Intracellular cytoplasmic proteins

Nuclearprotein

EGFR

HER2

ErbB3

ErbB4

IGF-1R

ADAM-15A

ADAM-15B

β-Catenina

c-Cbla

FAKa

Paxillina

p130CASa

β-Tubulina

ARAP-1

IRS-1

IRS-4

Erk5

β-Catenina

Akt

Erk

MAPK

PTEN

Paxillina

KAP3Aa

STAT3a

STAT5aa

STAT5ba

STAP-2 (BKS)

GNAS

FL139441

GapA-p65

C-Cbla

Dok1a

FAKa

Hsp90a

Hsp70a

p190RhoGAP

p130CASa

β-Tubulina

β-Catenina

Sam68

SLM-1

SLM-2

PSF

KAP3Aa

STAT3a

STAT5aa

STAT5ba

Dok1a

Hsp90a

Hsp70a

p27Kip1

aThese proteins are reported to have functions in different cellular compartments; however it has not yet been determined whether PTK6 affects the function of these proteins in all their localizations

PTK6 and Signaling Pathways

From the wide variety of substrates and interacting proteins that have already been identified (Table 1), it is clear that PTK6 plays a role in a number of different cellular processes and signaling pathways (Fig. 1). This is also apparent from the range of signaling molecules that activate PTK6, which include epidermal growth factor (EGF), heregulin (HRG), insulin-like growth factor (IGF), hepatocyte growth factor (HGF), osteopontin (OPN), and calcium ions.

PTK6 has been shown to associate with all members of the ErbB receptor family (reviewed in Hussain and Harvey 2014) and potentiates the proliferative effects of EGF by activating the phosphoinositide 3-kinase (PI3-K)/Akt signaling pathway. PTK6 is known to play a role in cell migration through the phosphorylation of paxillin, which is a ‘molecular scaffold’ that interacts with signaling molecules and a number of proteins that are involved in cell motility. In response to EGF, activated PTK6 phosphorylates paxillin resulting in the activation of Rac1 and an increase in cell migration. Treatment of breast cancer cells with the ErbB ligand HRG also increased cell migration, via activation of both Erk5 and an Erb-PTK6-Rac-p38 MAPK signaling pathway (reviewed in Goel and Lukong 2015; Ostrander et al. 2007).

PTK6’s interactions with the nuclear STAR (Signal Transduction and Activation of RNA) proteins (Sam68 and SLMs) and polypyrimidine tract-binding protein-associated splicing factor (PSF) are induced in response to EGF treatment. Phosphorylation of PSF and Sam68 (as well as the Sam68-like mammalian proteins, SLM1 and SLM2) by PTK6 results in inhibition of their RNA-binding activities. Reducing their RNA-binding capability is one mechanism of reducing the function of proteins that bind RNA. As these proteins regulate a number of RNA processing events, including alternative splicing, PTK6 activation could result in the posttranscriptional regulation of gene expression. In addition EGF-mediated activation of PTK6 induced phosphorylation of Sam68 which increased cell proliferation. This presumably occurred through suppressing the antiproliferative properties of Sam68 (Lukong et al. 2005; reviewed in Harvey and Burmi 2011).

PTK6 expression has also been linked to the potential regulation of IGF signaling. PTK6 interacts with the IGF-1R/IRS-1 complex resulting in increased activation of IGF-1R, as well as Akt. An increase in IGF-1-mediated, anchorage-independent cell survival was also observed in both breast and ovarian cancer cells (Irie et al. 2010). Similar effects on cell survival have also been shown in serum-stimulated breast cancer cells, where PTK6 again protected against cell death in suspension culture (Harvey et al. 2009). Interestingly, in both IGF-1 stimulated cells and lapatinib-resistant cells PTK6 protected cells from classical apoptosis/anoikis (Irie et al. 2010; Park et al. 2015), whereas the Harvey study showed that PTK6 protected breast cancer cells from cell death via autophagy. Taken together, these studies indicate that PTK6 can protect cells from different types of programmed cell death, and that this protection is through different mechanisms.

Furthermore, treatment of breast cancer cells with the Met receptor ligand, HGF, induced both activation of Erk5 and cell migration (Castro and Lange 2010). The PTK6/Erk5 interaction and the increased migration that was induced in response to HGF was not dependent on the kinase activity of PTK6, providing further evidence that some aspects of PTK6 function are not reliant on its kinase domain. This implies that PTK6 could coordinate the large signaling complexes that are required for cell migration, without directly phosphorylating components of the complex.

Most of the PTK6-mediated interactions and activation events result in altered cell behaviors such as increased proliferation, cell survival, migration, and the secretion of angiogenic factors, all of which are traits that are characteristic of tumor cells and are required for tumor development (reviewed in Hanahan and Weinberg 2000). It would appear from the majority of studies carried out in tumor cell lines, that PTK6 could play a central role in tumor progression, especially in breast cancer. In support of this hypothesis, Chakraborty and colleagues showed that treating cells with OPN resulted in PTK6 activation and an increase in vascular endothelial growth factor (VEGF) production. Combined with in vivo models, they were able to demonstrate that OPN triggers VEGF-dependent angiogenesis (formation of new blood vessels) and tumor growth as a result of PTK6 activation (Chakraborty et al. 2008).

In cells where PTK6 is physiologically expressed i.e., normal differentiating cells, the effects of PTK6 activation are distinct to those seen in tumor cells. When keratinocytes (skin cells) are treated with calcium, PTK6 is transiently activated and cell differentiation is induced, in contrast to the proliferation or migration seen in tumor cells. Recent evidence suggests that PTK6, the EGF receptor (EGFR), and a marker of differentiation (involucrin) may be coregulated during differentiation, and that the differentiation of normal primary human keratinocytes could be influenced by altered PTK6 expression (reviewed in Harvey and Burmi 2011; Goel and Lukong 2015).

It is clear that PTK6 signaling is diverse (Fig. 2), and that PTK6’s function with respect to signaling is different in normal differentiating cells to that in tumor progression. PTK6 has also been shown to associate directly with Akt (Zhang et al. 2005) and, in conjunction with results from several other studies, has led to the hypothesis that one of the PTK6’s roles in normal cells could be to constrain Akt activation, possibly to allow differentiation to occur. In tumor cells, the constraint is lost and the PI3-K/Akt pathway subsequently becomes activated, thereby upregulating the processes that are known to be involved in tumor growth.
Protein Tyrosine Kinase-6 (PTK6), Fig. 2

Potential biological effects of PTK6-mediated interactions

PTK6 Expression Profile

PTK6 expression is increased in many tumors compared to normal epithelial cells (reviewed Harvey and Burmi 2011) and this is most notable and most well-characterized in breast tissue. It is only recently that PTK6 expression was detected in normal breast cells (Peng et al. 2014), with previous studies demonstrating that up to 86% of breast cancers have elevated PTK6 expression and that the increase in expression correlated with an increase in tumor grade (reviewed Harvey and Burmi 2011) is mediated by several factors including NFκB, Sp1, HIF1α, and the glucocorticoid receptor and correlates with HER2 overexpression and/or amplification in some tumors (reviewed in Goel and Lukong 2015). This is important from a tumor development standpoint, as interaction of PTK6 protein with HER2 induces and prolongs the activation of the MAPK pathway which would result in an increased cell cycle progression and tumor cell proliferation and, in mouse models, PTK6 expression promotes ErbB2-induced tumorigenesis (Peng et al. 2015).

While not the whole picture, and the clinical significance is currently far from clear, a number of studies have also reported molecular changes that could lead to elevated PTK6 expression (reviewed Harvey and Burmi 2011), regulation by microRNAs (Haines et al. 2016), as well as missense and truncating mutations that could affect PTK6 function (reviewed Goel and Lukong 2015). This suggests that there are multiple mechanisms contributing to PTK6’s overexpression.

These findings, taken together alongside the current knowledge of PTK6’s multiple signaling roles in tumor cells, suggest that PTK6 is strongly implicated in tumor development. It could therefore be expected that PTK6 expression would have a negative impact on breast cancer patient survival and Kaplan-Meier survival analysis supports this conclusion (Pires et al. 2014).

Summary

There is little doubt that the role of PTK6 is complex. It depends on a number of factors including cellular localization, accessibility of binding partners, availability of extracellular signaling molecules, and potentially, at least in tumor cells, the extent to which PTK6 expression is elevated. Further studies are fundamental to unraveling the complex and distinct roles that PTK6 plays in both normal differentiating cells and in tumor development. Progress in the isolation and development of compounds that inhibit PTK6’s kinase activity, along with recent elucidation of the crystal structure, are fundamental to furthering our understanding of the distinctions between a prodifferentiation role in normal cells, and a potentially oncogenic role in tumor progression; this is key to the development of novel therapeutic agents that could target either context-specific or cell-specific molecular functions and/or interactions with minimal effects in other tissues.

See Also

References

  1. Brauer PM, Zheng Y, Evans MD, Dominguez-Brauer C, Peehl DM, Tyner AL. The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin. PLoS One. 2011;6(3):e14789. doi: 10.1371/journal.pone.0014789.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Castro NE, Lange CA. Breast tumor kinase and extracellular-signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res. 2010;12(4):R60. doi: 10.1186/bcr2622.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008;68(1):152–61. doi: 10.1158/0008-5472.CAN-07-2126.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Goel RK, Lukong KE. Tracing the footprints of the breast cancer oncogene BRK – past till present. Biochim Biophys Acta. 2015;1856:39–54. doi: 10.1016/j.bbcan.2015.05.001.PubMedPubMedCentralGoogle Scholar
  5. Hanahan D, Weinberg RA. Hallmarks of cancer. Cell. 2000;100:57–70.PubMedCrossRefGoogle Scholar
  6. Haines RJ, Beard Jr RS, Eitner RA, Chen L, Wu MH. TNFα/IFNγ mediated intestinal epithelial barrier dysfunction is attenuated by microRNA-93 downregulation of PTK6 in mouse colonic epithelial cells. PLoS One. 2016;11:1–18. doi: 10.1371/journal.pone.0154351.CrossRefGoogle Scholar
  7. Harvey AJ, Pennington C, Porter S, Burmi RS, Edwards DR, Court W, et al. Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. Am J Pathol. 2009;175(3):1226–34. doi: 10.2353/ajpath.2009.080811.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Harvey AJ, Burmi RS. Future therapeutic strategies: implications for Brk targeting. In: Gundez E, Gundez M, editors. Breast cancer: current and alternative therapeutic modalities. InTech; 2011. 413–35.Google Scholar
  9. Hussain HA, Harvey AJ. Evolution of breast cancer therapeutics: breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy. World J Clin Oncol. 2014;5(3):299–310. doi: 10.5306/wjco.v5.i3.299.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, et al. PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One. 2010;5(7):e11729. doi: 10.1371/journal.pone.0011729.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Kim HI and Lee S-T. Oncogenic Functions of PTK6 Are Enhanced by Its Targeting to Plasma Membrane But Abolished by Its Targeting to Nucleus. J Biochem. 2009;146(1):133-9. doi: 10.1093/jb/mvp050.Google Scholar
  12. Lukong KE, Larocque D, Tyner AL, Richard S. Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem. 2005;280(46):38639–47. doi: 10.1074/jbc.M505802200.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, Page MJ, Gusterson BA and Crompton MR. Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene. 1994;9(8):2383–2390.Google Scholar
  14. Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CJ. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res. 2007;67(9):4199–209. doi: 10.1158/0008-5472.CAN-06-3409.PubMedCrossRefPubMedCentralGoogle Scholar
  15. Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY. PTK6 inhibition promotes apoptosis of lapatinib-resistant HER2+ breast cancer cells by inducing Bim. Breast Cancer Res. 2015;17:86. doi: 10.1186/s13058-015-0594-z.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Peng M, Emmadi R, Wang Z, Wiley EL, Gann PH, Khan SA, Banerji N, McDonald W, Asztalos S, Pham TN, Tonetti DA, Tyner AL. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma memebrane in breast tumors. Oncotarget. 2014;15(5):6038–48. doi: 10.18632/oncotarget.2153.CrossRefGoogle Scholar
  17. Peng M, Ball-Kell SM, Tyner AL. Protein tyrosine kinase 6 promotes ErbB2-induced mammary gland tumorigeneses in the mouse. Cell Death Dis. 2015;6:e1848. doi: 10.1038/cddis.2015.210.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Pires IM, Blokland NJ, Broos AW, Poujade FA, Senra JM, Eccles SA, Span PN, Harvey AJ, Hammond EM. Hif-1α-independent hypoxia-induced rapid PTK6 stabilzation is associated with increased motility and invasion. Cancer Biol Ther. 2014;15(10):1350–7. doi: 10.4161/cbt.29822.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Zhang P, Ostrander JH, Faivre EJ, Olsen A, Fitzimmons D, Lange CA. Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem. 2005;280(3):1982–91. doi: 10.1074/jbc.M412038200.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Institute for Environment Health and SocietiesBrunel UniversityLondonUK